Please login to the form below

Not currently logged in

HIV drug approved

Full marketing authorisation has been granted to Boehringer for its HIV protease inhibitor, Aptivus (tipranavir)
Full marketing authorisation has been granted to Boehringer for its HIV protease inhibitor (PI), Aptivus (tipranavir).

The European Commission has approved the drug, which has been developed to suppress HIV in treatment-experienced patients who have acquired a resistance to other PIs.

"This full approval demonstrates the confidence that the authorities have in the benefit of Aptivus for patients with a resistant virus," said Dr Andrea Barner, member of the board of Boehringer Ingelheim and responsible for research, development and medicine.

HIV has progressed to a point where a growing number of people across Europe are carrying strains of the disease which are resistant to various therapeutic options. Boehringer says that a study in Spain showed that 43 per cent of patients treated for more than eight years have more than five protease resistance mutations.

Aptivus is the first non-peptidic PI treatment and showed good anti-viral activity during trials. Over 1,400 patients were involved in two large studies, Resist I and II, located at different centres. It was the largest evaluation conducted to date of treatment-experienced patients, and proved the efficacy and safety of the medicine, which has been shown to combat drug-resistant strains of HIV.

7th May 2008


Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018